BBI Solutions

Activities: Ingredients Analysis

Trending Articles

  1. OINDPs: Nosey about recent developments? OINDPs are a user friendly and efficacious alternative to injectables in several disease areas
  2. Transforming healthcare with patient centricity In this opinion article, John Kytariolos, Head of Clinical and Scientific Affairs at Adragos Pharma, discusses patient-centric dosage forms, their properties and the impact...
  3. Catalent and AstraZeneca to expand support for COVID-19 vaccine AZD1222 Catalent will prepare the Harmans facility, close to Baltimore-Washington International (BWI) airport, to enable multiple production trains to run in parallel to produce the...
  4. Compact process thermostat for efficient temperature control in the laboratory The temperature control system is designed for the accurate temperature control of small research reactors between -40 to +200 °C
  5. AviadoBio expands presence at Canary Wharf The company has acquired 11,000 sqft of laboratory and office space in Canary Wharf to accommodate the growing team

Upcoming event

Making Pharmaceuticals

23–24 April 2024 | Exhibition | Coventry, UK See all

Related Content

Ingredients

BBI Solutions completes reagent manufacturer acquisition

BioTeZ is a manufacturer of reagents and finished tests for the in-vitro diagnostics (IVD) market
Finance

BBI creates new jobs to support next phase in COVID-19 home test development

The lateral flow antibody test that can be used by people in their homes to determine if they have an antibody response to COVID-19
Research & Development

BBI Solutions partners to distribute COVID-19 antigens in China

The Native Antigen Company has agreed distribution rights with BBI to provide coronavirus reagents in China
Ingredients

BBI Solutions expands infectious disease reagent suite

BBI Solutions has demonstrated internal antibody development capabilities and has also expanded its infectious disease reagent suite

BBI Solutions increases capacity for transferrin production

BBI Solutions (BBI) has invested in its facilities and resources to increase the capacity of cell culture native human transferrin production by up to 40%
Subscribe now